Extended-release formulations of the somatostatin analogues, octreotide and lanreotide, are first-line medical therapies for patients with acromegaly who have contraindications for, or are not cured by, surgical intervention and/or radiotherapy. touchENDOCRINOLOGY are joined by Dr Diego Ferone (University of Genova, Italy) to discuss the efficacy and safety of CAM2029 in acromegaly evaluated in a 6-month, randomized, double-blind, placebo-controlled phase 3 trial (NCT04076462).
The abstract ‘THU-070 – Randomized, Placebo-Controlled Phase 3 Trial Protocol Assessing the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients with Acromegaly‘ was presented at The Endocrine Society (ENDO23) annual meeting in Chicago,15-18 June 2023.
Questions
- What are the current first-line medical therapies for acomegaly? (00:42)
- What was the rationale and design of the trial? (01:47)
- What were the primary and secondary endpoints, and were they met? (06:32)
- Please summarize the key findings and results? (08:30)
- What impact will these results have on future clinical practice, and are further studies planned? (11:00)
Disclosures: Diego Ferone is a consultant for Camurus, has received grant/research support from Camurus, Recordati and IPSEN, is a member of the advisory board for Recordati, Novartis-AAA and has received honoraria/honorarium from Recordati and Novartis-AAA.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed as a highlight of ENDO 2023
